{"schema_version":"secwatch.filing_event.v1","accession":"0001232524-23-000051","form_type":"8-K","ticker":"JAZZ","cik":"0001232524","company_name":"Jazz Pharmaceuticals plc","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.465301+00:00","generated_at":"2026-06-08T08:45:15.420989+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Jazz Pharmaceuticals Reports Q3 2023 Revenue of $972M, Raises Full-Year Guidance","bullets":["Xywav net product sales grew 30% year-over-year to $331.6M; total oxybate revenue annualizing at $1.9B","Epidiolex net product sales up 9% to $213.7M; Rylaze up 43% to $104.9M","Company raises 2023 total revenue guidance to $3.75-$3.875B and oncology guidance to $975M-$1.05B","Plan to initiate zanidatamab rolling BLA submission this year for accelerated approval in 2L biliary tract cancers","GAAP net income of $146.8M vs. loss of $19.6M in Q3 2022; non-GAAP adjusted net income $340.1M"],"urls":{"canonical":"https://secwatch.observer/filing/0001232524-23-000051","json":"https://secwatch.observer/filing/0001232524-23-000051.json","markdown":"https://secwatch.observer/filing/0001232524-23-000051.md","text":"https://secwatch.observer/filing/0001232524-23-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1232524/000123252423000051/0001232524-23-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1232524/000123252423000051/jazz-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:45:15.420989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6e0103198a3ce9f76945900d985c0eb67bbeaff0","claim":"Jazz Pharmaceuticals plc updated its the quarter ended September 30, 2023 guidance (raised).","evidence_excerpt":"On November 8, 2023, Jazz Pharmaceuticals plc (the “Company”) issued a press release (the “Press Release”) announcing financial results for the Company for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252423000051/0001232524-23-000051-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}